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Development of a patient decision aid for prevention of
myocardialinfarctionintype2diabetes–rationale,design
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Entwicklung einer Entscheidungshilfe zur Herzinfarktprävention für
Patienten mit Typ 2 Diabetes – Grundlagen, Design und Pilotierung
Abstract
Aims: Development and testing of a decision aid about prevention of
myocardial infarction for persons with type 2 diabetes.
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Methods: Development and testing were guided by the UK Medical
Research Council’s guidance for the development and evaluation of Ingrid Mühlhauser
1
complex interventions. This comprised a systematic literature review,
afocusgroupof9potentialproviders,modellingaprototype,interviews 1 University Hamburg, Unit of
Health Sciences and toqualitativelyexploreunderstandingandadditionalinformationneeds,
and revision of the decision aid. Education, Hamburg,
Germany Results: The decision aid includes evidence-based information, a tool
for individual risk-assessment, worksheets, and an action plan. Five
diabetes educators and 15 patients underwent two 60-minutes face-
to-faceinterviews, firstlybrowsingthedecisionaidforthefirsttimeand
then after using it. Both groups differed in their ratings. Overall, the
decision aid was rated to present essential information in a complex
but understandable and unbiased manner. Difficulties involved under-
standing of terminology and risk interpretation. “Social status as a risk
factor” was the most challenged content by educators but considered
as highly important by patients. The risk assessment tool was used in-
adequately. 5 patients allocated themselves into false risk categories.
Afterrevisionofthetool,all12patientswhowererecruitedforreassess-
ment used the tool correctly.
Conclusion: The decision aid was evaluated with diabetes educators
and patients. Qualitative data analysis revealed aspects for revision.
The decision aid is planned to be part of a shared decision making
programme, comprising a strategy for patient counselling and educa-
tional modules addressed to providers. Quantitative evaluation is re-
quired to assess its effectiveness.
Keywords: diabetes mellitus type 2, acute coronary syndrome,
cardiovasculardiseases,decisionsupporttechniques,patienteducation,
patient participation
Zusammenfassung
Zielsetzung: Entwicklung und Evaluation einer Entscheidungshilfe zur
Herzinfarktprävention für Patienten mit Typ 2 Diabetes.
Methodik: Entwicklung und Evaluation der Entscheidungshilfe folgten
der Leitlinie des UK Medical Research Councils zur Entwicklung und
Evaluation komplexer Interventionen. Dies beinhaltete eine syste-
matische Literaturanalyse, einen Fokusgruppenworkshop mit 9 poten-
tiellen Anbietern, Erstellung eines Prototyps der Entscheidungshilfe,
InterviewszurqualitativenErfassungvonVerständnisundzusätzlichem
Informationsbedarf und Revision der Entscheidungshilfe.
Ergebnisse:DieEntscheidungshilfebeinhaltetevidenzbasierteInforma-
tionen, ein Instrument zur Herzinfarktrisikoprognose, Arbeitsblätter,
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Research Article OPEN ACCESSsowieeinenAktionsplan.FünfDiabetesberaterund15Patientenwurden
zweimal60Minuteneinzelninterviewt,zuerstwährenddeserstmaligen
Durchsehens und dann nach Verwendung der Entscheidungshilfe.
BeideGruppenkamenzuunterschiedlichenEinschätzungen.Insgesamt
wurden die Inhalte als wichtig, deren Darstellung als komplex aber
verständlich und unverzerrt bewertet. Schwierig waren das Verstehen
derverwendetenFachterminologiesowiedieInterpretationvonRisiken.
DieDiabetesberaterstellteninsbesonderedasThema„Sozialstatusals
Risikofaktor“ infrage, während es von den Patienten als sehr wichtig
gewertet wurde. Das Risikoprognoseinstrument wurde nicht richtig
verwendet, 5 Patienten ordneten sich falschen Risikokategorien zu.
NachÜberarbeitungwurdeesvonallen12Patienten,diezurwiederhol-
ten Evaluation rekrutiert worden waren, richtig verwendet.
Fazit:DieEntscheidungshilfewurdemitDiabetesberaternundPatienten
evaluiert. Die qualitative Datenanalyse ergab Aspekte für die Revision.
Die Entscheidungshilfe ist als Teil eines Entscheidungshilfeprogramms
(shared decision making programme) geplant. Dies beinhaltet eine
Strategie zur Patientenberatungsowie ein Schulungsmodulfür potenti-
elle Anbieter. Für die Evaluation der Effektivität der Entscheidungshilfe
sind quantitative Methoden notwendig.
Introduction
People with type 2 diabetes are at increased risk of
coronary heart disease (CHD). An array of behavioural
directives is imposed on them such as quitting smoking,
increasing exercise, normalising weight, and adhering to
monitoring, dietary and medication prescriptions. How-
ever, evidence on effectiveness of many of these meas-
ures is limited and some of these measures do more
harm than good [1]. Compliance to long term treatment
is poor, even with the most promising interventions such
as blood pressure control and statin use [2], [3], [4].
Lackofpatientinvolvementindecisionmakinghasbeen
suggested as one reason for limited treatment success
[5], [6]. Involving patients with diabetes in decision
makingmayimproveknowledgeandenhancediscussions
betweenpatientsandtheirdoctorsaboutCHDprevention
[5], [6].
A “good decision” can be characterised by the extent to
which it is informed and consistent with the patient’s
personal values [7]. Patient decision aids (DAs) are de-
signed to help people make specific and deliberative
choices among options by providing information about
the options and outcomes that is relevant to a person's
health status [8]. DAs may include estimates of probable
treatment effects, exercises, and strategies for decision-
making. DAs could be part of regular patient education
curricula,specific decision-makingprogrammesor could
be offered during patient counselling. Educating and in-
formingpatientsarealreadykeycomponentsofdiabetes
care. Diabetes educators are increasingly asked to com-
municate research results to patients. The use of DAs
may facilitate patient counselling.
In November 2008 we updated former systematic litera-
turesearches[9]usingthe CochraneInventory,PubMed,
Embase, CINAHL, PsycINFO, and PSYNDEXplus [1].
Fourteen publicly available DAs about cardiovascular
prevention were identified [6], [10], [11] [12], [13], [14],
[15], [16], [17], [18], [19], [20], [21], [22], [23], [24],
[25], [26]. One of them, Statin Choice, was specifically
designed for people with type 2 diabetes [22], [23], [24],
[25], [26]. One additional diabetes DA was identified by
personal contact [27] (for characteristics and quality as-
pects see Table 1). Statin Choice [24] focuses on statin
treatment. It meets nearly all quality criteria established
by the International Patient Decision Aid Standards
(IPDAS)Collaboration[8].Weidentifiedthreepublications
ondevelopmentandevaluationofthisDA[24],[25],[26].
Onereportedarandomisedcontrolledtrial(RCT)inwhich
theDAwasratedmorehelpfulthanastandardeducation-
alpamphlet.Itwasfoundeffectiveconcerningknowledge,
improvingpatients’estimationoftheircardiovascularrisk
and of potential risk reductions with statin drugs, and it
decreased decisional conflict [25].
TheHealthDialogDA[27]promotesmodificationofhealth
behavioursuggestingahierarchyoftargetswithemphasis
on control of blood pressure and cholesterol. Risk infor-
mation on benefits and harms is not provided. Data
sourcesarenotlisted.Evidenceabouttheimplementation
of this DA in clinical practice was not identified.
The present article describes development and pilot
testing of a DA about prevention of myocardial infarction
forpatientswithtype2diabetes(http://www.chemie.uni-
hamburg.de/igtw/Gesundheit/images/pdf/Decision_Aid_
HerzinfarktpraeventionDM2.pdf).
Methods
DAs are complex interventions comprising a number of
interactive components [28]. Therefore, the UK Medical
Research Council’s guidance [29] was used to structure
modellingandevaluationofthisDA.Thiswidelyaccepted
guidancewasdevelopedtosupporttransparentdevelop-
ment and evaluation of complex interventions [30], [31].
The local ethics committee approved the study protocol.
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Rationaleanddesignofthedecisionaid
TheDAisdesignedforpeoplewithtype2diabeteswithout
history or clinical signs of coronary disease, major other
cardiovascular disease or diabetic late complications. It
is aimed to be used by patients to prepare them for con-
sultations with their diabetes educator and/or their gen-
eral practitioner. Patients should have participated in a
structured diabetes education programme previously.
The DA targets lifestyle changes or drug interventions
recommendedforprimarycoronaryprevention.Objective
is to improve the quality of decision-making. This means
thatpatientsunderstandandclarifypersonalimportance
of outcomes and probabilities of their occurrence, and
participate in decision-making actively. This approach is
ethicallyjustifiedandimplicatedbyactioncontroltheories
such as the theory of planned behaviour [32]. According
to this model, behaviour is influenced by attitudes to the
behaviour, subjective norm (e.g. perceived physician’s
attitudes), and perceived and actual behaviour control.
The DA provides evidence-based information to resolve
knowledge deficits in order to strengthen behaviour
control. Information about probabilities of outcomes
tailoredtotheindividualriskisaimedatrealigningunreal-
istic expectations. Worksheets are designed to help de-
liberating about individually important information. The
DA is in German language.
The project was designed and executed by the three
authors covering three research areas (education and
health sciences, diabetology and internal medicine, psy-
chology).TheprotocolhasbeenbasedonMATRIX,aguide
for systematic development and evaluation of DAs [33].
The IPDAS quality criteria [34] were considered.
Evidence was gathered and “translated” into simple lan-
guage suitable for patients. Selection and presentation
of research data followed recent criteria for evidence
based patient information and shared decision making
[35]. We used a background paper of the German dia-
betes disease management programme [36] and the
consentguidance bytheBritishGeneralMedicalCouncil
[37].Updateswereperformedbysystematicallysearching
the Cochrane database of systematic reviews, Medline,
and Embase. Articles were selected according to validity,
patient relevance and clinical importance. References
are listed in the DA.
Information on risk factors and available treatment op-
tions (Table 2) is provided on a simple level. 100-stick
figure pictograms and bar graphs visualise the risk of
having a heart attack and treatment effect probabilities
(examplesinFigure1andFigure2).Anappendixprovides
additional information (e.g. reliability of individual risk
prognosis). A glossary explains important technical and
medical terms.
Users are guided to estimate individual risk of having a
myocardial infarction in the next ten years and to find
tailored information about statin treatment effects. The
PROCAM risk score [38] and data of the German Federal
Health Monitoring [39] were used to calculate the risk in
roughcategories(Figure3).Riskestimatesdonotcontra-
dict with current recommendations [36], [40].
Component modelling
Adraftversionwasevaluatedinafocus-groupofpotential
providers during a two-hour workshop held at the 16th
Forum of Quality in Health Care in Munich 2006. Three
physicians,twopsychologistsandfourpatientcounsellors
were invited to reflect and criticise the concept. Com-
mentswereclusteredaccordingtotopics.Werevisedthe
DA based on qualitative data synthesis.
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Figure 1: Heart attack risk of 6%
Pilot testing among providers
Qualitative methods were used to gather insight into
1) difficulties of understanding the contents of the DA,
2) appropriateness of complexity, 3) completeness, and
4) expected applicability.
Five diabetes educators were recruited from diabetes
clinics in Hamburg. Each underwent two semi-structured
face-to-faceinterviews conducted by two researchers. All
participantsgavewritteninformedconsent.Allinterviews
weredocumentedinwrittenform.Atthebeginningofthe
first interview, we explored the spontaneous orientation
within the DA. Using the concurrent “think-aloud” tech-
nique [41], [42], each educator was encouraged to ex-
press thoughts and associations loudly while browsing
the contents. Subsequently, we explored detailed under-
standingofpassagesaboutriskprognosis.Eacheducator
was asked to shortly summarise the content. Difficulties
of understanding were intensively discussed. Each edu-
cator received a short evaluation guide for homework.
The guide comprised three tasks: 1) “please mark pas-
sages (texts and figures) that you do not understand”;
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Figure 3: Tool as used in the decision aid for the assessment of a 10-year risk of having a heart attack for people with type 2
diabetes
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informedandsupportedindecisionmaking?”3)“Please
reflect on passages or topics, which you think that more
information is necessary”.
The second interviews were conducted two weeks later.
The tasks were intensively discussed.
Data analysis
Data analysis passed four steps: identifying units of
analysisinthetranscripts,allocatingthestatementsinto
categories, interpreting the data, and extracting needs
of revision of the DA. Categories were 1) content,
2) complexity, 3) structure/orientation, 4) media and
layout (colours, illustrations etc.), and 5) patient
centeredness (Table 3, Table 4). Comments that could
notbeallocatedintoacategoryweredocumentedsepar-
ately.Tworaters(ML,JK)discussedandinterpretedeach
statement until consensus about the allocation was
achieved. Inter-rater-agreement was not assessed. De-
cisionsonrevisionweremadeinadiscoursebyanexpan-
ded research group (IM, ML, JK, MB).
Pilot testing among patients
Evaluation among patients comprised two studies. We
explored 1) difficulties of understanding the contents of
theDA,2)appropriatenessofcomplexity,and3)addition-
al information needs (completeness). Participants were
recruited by screening the registers of a diabetes outpa-
tient clinic in Hamburg.
For the first study, 15 women and men at the age
between 40 and 69 years with type 2 diabetes and
without history of CHD were included selected according
to age, gender, blood pressure, and status of smoking
(Table 5). Study procedures were identical to the educa-
tor’s interviews. In addition, passages according to spe-
cific risk factors were allocated according to individual
risk profiles (Table 5). Patients were asked to summarise
those contents. Difficulties were intensively discussed.
Each participant received a short evaluation guide for
homework comprising two tasks: 1) “please mark pas-
sages (texts and figures) that you do not understand”;
2) “Do you feel sufficiently informed? Please, reflect on
passages or topics, which you are interested to learn
more”.
The second interviews were conducted two weeks later.
The tasks were intensively discussed. Both interviews
were analysedanalogousto those among the educators.
ThesecondstudywasconductedafterrevisionoftheDA.
Thecoronaryriskassessmenttoolwasreassessed,which
had shown insufficient performance in the first study.
Twelve women and men (40–70 years) with type 2 dia-
betes were recruited by screening the registers of the
diabetesclinicagain.Face-to-faceinterviewswereunder-
taken to explore how the participants use the revised
coronary risk assessment tool for an imaginary patient.
Each hypothetical patient varied across coronary risk
categories.Usingconcurrent“think-aloud”[41],[42],the
participants were encouraged to express their thoughts
loudly while using the tool.
Results
Pilot testing among providers
Fiveeducatorswereenrolled;oneofthemwasmale,four
of them female. All had a minimum of 10 years working
experience in diabetes education and counselling.
Eachinterviewlasted60minutes.Typicalstatementsare
displayed in Table 3. The DA was anticipated helping pa-
tients to understand the concept of risk prognosis and
the role of type 2 diabetes. A general understanding of
coronaryriskwasfoundnecessarytoreflectbenefitsand
risks of preventive options. It was also mentioned that
the “multiple risk factor approach” might be too difficult
to understand.
The complexity of the DA was considered as very high
emphasisingthatthetargetgroupishighlyheterogeneous
related to social status and level of literacy. It was pro-
posed to delete passages that are “too statistical” and
to develop versions providing different levels of informa-
tion.
The DA was found to guide patients through the decision
making process in an acceptable and logical way and
that it would help them to prepare for and reach a de-
cision.
The media used were considered appropriate. The edu-
cators proposed to rearrange the layout (e.g. code of
colours in terms of a recurrent theme) and to include an
initial “quick guide” facilitating orientation. Providing the
includedillustrations(risk,benefitsandharms)asleaflets
supporting patient education and counselling was also
proposed.
TheeducatorsperceivedtheDAmainlyaspatientcentred.
However,theychallengedthetechnicalstyleoflanguage,
which was chosen to provide information in an unbiased
way. They suggested “talking” to patients in a “more
personalandnon-technical”mannerandtoincludesome
kind of case reports for illustration purposes. The invita-
tion to decide on preventive options in an “autonomous”
or “shared” manner was anticipated to overstrain most
patients.
The most controversial content related to “social status
as a risk factor”. Inconvenience was expressed to com-
municate a factor, “which can not be modified or exactly
quantified”, “whose causes are difficult or impossible to
explain”,or“whichmightdiscriminatepatientswithalow
social status”. It was also suggested to lay emphasis on
social support in order to motivate people to become
actively involved in their social environment.
In preparation for the second interviews, all educators
had reviewed the DA intensively. It was found to have an
appropriateformat.Alleducatorsmentionedthatcommu-
nicating the “multiple risk factor approach” is necessary
to support decision-making. Difficulties were expected
concerning the understanding of the term risk and indi-
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vidual risk perception. Worksheet and action plan were
expected to structure decision making and to define a
preventive strategy. The chapter “social status as a
coronary risk factor” was challengedagain by expressing
concerns to implement this topic into patient education
and counselling.
All educators would support the implementation of this
DA. Conditions of implementation were considered as
optimalwithineducationcurriculaandpatientcounselling.
The DA was expected to facilitate discussions between
patients, educators and doctors and to support shared
decision making.
Pilot testing among patients
Fifteenpatientswereenrolledinthefirstqualitativestudy
(Table 5). Median age was 57 years; all finished a
minimum of 8 years elementary school; five were of
higher educational level. Both interviews lasted approx.
60 minutes. Typical statements are displayed in Table 4.
Spontaneous orientation was rated as good. All parti-
cipants could describe the main topics of the DA. The
contents about risk prognosis were mainly reproduced
correctlybutdifferedincompletenessandprofoundness.
The overall complexity was considered as high. Some
passages were found “too statistical”. However, no par-
ticipant felt overstrained.
7/12 GMS Psycho-Social-Medicine 2009, Vol. 6, ISSN 1860-5214
Lenz et al.: Development of a patient decision aid for prevention ...Table 4: A sample of statements* from the first and second interviews with patients in categories
8/12 GMS Psycho-Social-Medicine 2009, Vol. 6, ISSN 1860-5214
Lenz et al.: Development of a patient decision aid for prevention ...Table 5: Patients’ allocation according to moderating variables
Graphicalillustrationsweremainlyconsideredashelpful.
Most participants correctly interpreted the probabilities
presented using 100 stick figure pictograms. The risk
assessment tool was not used correctly by five partici-
pants as they allocated themselves to false risk categor-
ies.
Each passage specific for a risk factor was evaluated by
3 participants. The passage about glucose control was
rated as easy to understand. One participant expressed
difficulties in transferring the findings of study results to
hisindividualsituation.Similarresultswerefoundforthe
passages about “high blood pressure” and “use of stat-
ins”. The risk specific information about statin use was
correctly identified by all participants. The information
aboutthe“socialfactor”wasconsideredashighlyimport-
ant and proposed to be communicated even more exten-
sively. Patients also expressed concerns that this might
discriminate patients with a low social status.
The chapter about smoking was easily understood. How-
ever, it was challenged that the information contributes
to “quitting smoking”, since smoking was not a matter of
lacking knowledge about risk.
In preparation for the second interviews, all participants
had reviewed the DA intensively. The DA was rated as
helpful; the amount of information was mostly rated as
“just right”; some asked for additional information (e.g.
about stress and smoking as social factors and brands
of statins available on the German market).
Several passages were rated as difficult to understand.
Some participants reported that they had to read some
passages several times until they understood the mes-
sage. Most participants reproduced the term coronary
risk and the “multiple risk factor approach” correctly. It
was mentioned that too many statistics could be confus-
ing.Someexpressedproblemsinunderstandingtechnical
terms such as “any diabetes related endpoint”, “intensi-
fied treatment”.
The overall structure could easily be followed. Some
participants felt confused by the amount of information
and claimed more structuring elements such as picto-
grams and accentuated key messages. The 100 stick
figurepictogramswereratedhelpfultoreflectonbenefits
andharms.Someparticipantsproposedtoaddbargraphs
to simplify the comparison of proportions.
The DA was felt to provide good decision support. The
worksheet about quitting smoking was felt needless.
Some participants stated that they learned to ask “the
right questions” to the doctor.
All participants were very interested to use a validated
and revised version. Similar to the educators, conditions
of implementation were considered being optimal within
diabetes patient education curricula and counselling.
Twelve patients were enrolled in the second study to re-
assess a revised version of the risk assessment tool
(Figure 3). Seven participants were women; median age
was 56 years. All finished a minimum of 8 years elemen-
tary school. The revised coronary risk assessment tool
showed optimal performance. No participant expressed
difficultiesinusingitandallwereabletocorrectlyallocate
risk profiles.
Revision of the decision aid
Dataanalysisrevealedseveralaspects,whichcontributed
to the revision of the DA. E.g. technical terms were ex-
plained more intensively; the layout (headlines, colours,
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plified; 100 stick figure pictograms illustrating benefits
andharmsweresupplementedbybargraphstofacilitate
the comparison of proportions; the coronary risk assess-
ment tool was simplified and explained in more detail.
Despite patients concerns, the chapter about smoking
cessationremained.Quittingsmokingishighlyimportant
comparedtootherpreventiveoptions.Thechapterabout
glucose control was updated because of new evidence
from the recent ACCORD trial. The current version of the
DA (http://www.chemie.uni-hamburg.de/igtw/
Gesundheit/images/pdf/Decision_Aid_Herzinfarkt
praeventionDM2.pdf) contains 65 pages comprising
seven components (Table 2).
Discussion
Following the UK Medical Research Council’s guidance
for the development and evaluation of complex interven-
tions[29],wedescribedthetheoreticalconcept,compon-
ent modelling and preliminary qualitative evaluation of
this DA (http://www.chemie.uni-hamburg.de/igtw/
Gesundheit/images/pdf/Decision_Aid_Herzinfarkt
praeventionDM2.pdf) in detail. At this stage of develop-
ment, qualitative studies were necessary to gather an in-
depth understanding of how providers and users under-
stand the DA’s objectives, content and structure, how
they anticipate its applicability, and which additional in-
formation needs may exist. Representativeness and
transferability of these studies are limited, due to their
qualitative design. Further evaluation needs to include
quantitative methods to assess the DA’s effectiveness.
The DA was evaluated within its particular decision mak-
ing context including German speaking patients. An Eng-
lish translation is under development. The evaluation
suggestedthatmostpartsoftheDAwereunderstandable
and that information needs were mainly satisfied. Inter-
estingly, we found discrepancies between the patients’
understanding and the patients’ understanding anticip-
ated by the diabetes educators. E.g. while educators ex-
pected that many patients could be overstrained, most
patients could easily follow contents and structure. Edu-
cators’ anticipations that contents related to the social
statusasariskfactorcouldbemisunderstoodordiscrim-
inate, were not confirmed by patients’ comments.
We plan to develop additional components that are ne-
cessaryforasuccessfulimplementation.E.g.an evidence
table is going to be implemented, which includes an
overviewofavailablepreventiveoptionsandprobabilities
of benefits and harms. Graphical illustrations are going
to be combined in a handbook to support risk communi-
cation in patient education curricula and counselling. Fi-
nally, the DA is planned to be the core of a shared de-
cision making programme, which comprises a strategy
for patient counselling and an introductive educational
module that addresses providers (diabetes educators
andspecialisednurses).Effectivenessofthisprogramme
willbeevaluatedover12monthswithinaRCT.Longterm
implementationwillbesurveyedinobservationalstudies.
Notes
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